LGND News and Press, Ligand Pharmaceuticals Incorporated From 07/17/19

Thoughts about performance presentation Due to a mix of personal, professional and technical reasons more than 3 weeks have passed since my last article "Do Not Sell In May (June) And Go Away; Look At These Buy Candidates" was published. There have been interesting developments both in the...

SHELBURNE, Vt ., July 16, 2019 /PRNewswire/ -- Lemelson Capital Management, LLC (LCM), a private investment management firm, today announced performance results for its flagship Amvona Fund, LP. (The Fund). For 1H 2019, The Amvona Fund returned 70.27 percent net of all fees and expenses, ...

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report second quarter 2019 financial results on July 30, 2019. Ligand’s CEO John Higgins, President and COO Matt Foehr, and Executive Vice President and CFO Matt Korenberg will host the conference call. ...

Ligand Pharmaceuticals ( LGND +1.6% ) is up on below-average volume on the heels of positive results from a Phase 1 clinical trial assessing the safety and pharmacokinetics of CE-Iohexol, its next-generation, Captisol-enabled diagnostic imaging contrast agent that it says is less toxic t...

Study achieved primary endpoint demonstrating pharmacokinetic bioequivalence between Captisol-enabled Iohexol and OMNIPAQUE™ Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced positive top line results from a Phase 1 clinical trial of its internal Captisol-en...

Ligand Pharmaceuticals ( LGND -0.5% ) has licensed exclusive global rights to its Captisol technology to SQ Innovation AG for use in a high-concentration formulation of diuretic furosemide for the treatment of edema in heart failure patients. More news on: Ligand Pharmaceuticals Incorp...

SQ Innovation will use Ligand’s Captisol technology to achieve a smaller delivery volume for more cost-effective diuretic treatment in heart failure. The smaller delivery volume enables use of established drug container and device technology developed for insulin and other biol...

Ligand Pharmaceuticals (NASDAQ: LGND ) launches a public offering of common stock. Price, volume and terms have yet to be announced. More news on: Ligand Pharmaceuticals Incorporated, Takeda Pharmaceutical Company Limited, Healthcare stocks news, Read more ...

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that Sage Therapeutics has launched ZULRESSO™ (brexanolone) injection, which was approved by the U.S. Food and Drug Administration (FDA) on March 19, 2019, and is the first and only treatment specifically approved for p...

Intro to my approach You might have noticed in my previous articles how I mentioned this or that ticker as a result of running this or that screen. Indeed, I had, until 2 weeks ago, worked for over 6 months on performing hundreds and hundreds of backtests based on a number of multi-factor st...